サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：月経前症候群 (PMS) 治療薬の世界市場 (2022～2030年)：成長・将来の展望・競合分析
市場調査レポート
商品コード
1182394

月経前症候群 (PMS) 治療薬の世界市場 (2022～2030年)：成長・将来の展望・競合分析

Pre-Menstrual Syndrome Treatment Market - Growth, Future Prospects and Competitive Analysis, 2022 - 2030
出版日: | 発行: Acute Market Reports | ページ情報: 英文 118 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
月経前症候群 (PMS) 治療薬の世界市場 (2022～2030年)：成長・将来の展望・競合分析
出版日: 2022年11月30日
発行: Acute Market Reports
ページ情報: 英文 118 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

月経前症候群 (PMS) 治療薬の市場では、現在、PMSの有病率の増加、PMSと一般的な治療オプションに関する認知度の上昇などから、北米および欧州地域が優位を示しています。一方、アジア太平洋および中東・アフリカ地域は、PMS治療薬を提供する製造業者に有利な機会を提供しています。出産適齢期の女性が多く、識字率や労働人口が増加していることが、これらの地域における事業機会の拡大に大きく貢献しています。また、女性や母親の健康に焦点を当てた政府の取り組みやキャンペーンが増加していることも、市場の成長をさらに後押ししています。

当レポートでは、世界の月経前症候群 (PMS) 治療薬の市場を調査し、市場概要、市場成長への各種影響因子の分析、市場規模の推移・予測、各種区分・地域/主要国別の内訳、主要企業のプロファイルなどをまとめています。

目次

第1章 序文

第2章 エグゼクティブサマリー

第3章 月経前症候群 (PMS) 治療薬市場：競合分析

  • ベンダーの市場における位置づけ
  • ベンダーの採用戦略
  • 主要産業戦略
  • ティア分析：2021年・2030年

第4章 月経前症候群 (PMS) 治療薬市場：マクロ分析・市場力学

  • 世界市場の規模：2020-2030年
  • 市場力学
    • 市場促進要因
    • 市場抑制要因
    • 主な課題
    • 主な機会
  • 促進要因・抑制要因の影響分析
  • シーソー分析

第5章 月経前症候群 (PMS) 治療薬市場：薬剤タイプ別

  • 市場概要
  • 成長・収益分析：2021年・2030年
  • 市場の分類
    • 鎮痛剤（鎮痛剤）
    • 経口避妊薬（OCP）
    • 性腺刺激ホルモン放出ホルモン（GnRH）
    • 抗うつ薬
    • 卵巣抑制剤
    • 利尿薬
    • ベンゾジアゼピン

第6章 北米の月経前症候群 (PMS) 治療薬市場

  • 市場概要
  • 月経前症候群 (PMS) 治療薬市場：薬剤タイプ別
  • 月経前症候群 (PMS) 治療薬市場：地域別

第7章 英国およびEUの月経前症候群 (PMS) 治療薬市場

  • 市場概要
  • 月経前症候群 (PMS) 治療薬市場：薬剤タイプ別
  • 月経前症候群 (PMS) 治療薬市場：地域別

第8章 アジア太平洋の月経前症候群 (PMS) 治療薬市場

  • 市場概要
  • 月経前症候群 (PMS) 治療薬市場：薬剤タイプ別
  • 月経前症候群 (PMS) 治療薬市場：地域別

第9章 ラテンアメリカの月経前症候群 (PMS) 治療薬市場

  • 市場概要
  • 月経前症候群 (PMS) 治療薬市場：薬剤タイプ別
  • 月経前症候群 (PMS) 治療薬市場：地域別

第10章 中東およびアフリカの月経前症候群 (PMS) 治療薬市場

  • 市場概要
  • 月経前症候群 (PMS) 治療薬市場：薬剤タイプ別
  • 月経前症候群 (PMS) 治療薬市場：地域別

第11章 企業プロファイル

  • Alva-Amco Pharmacal Cos., Inc.
  • Bayer, Inc.
  • Chattem, Inc.（Sanofi）
  • DEKK-TEC, Inc.
  • G. R. Lane Health Products Ltd
  • McNeil Consumer Healthcare
  • MetP Pharma AG
  • Pherin Pharmaceuticals, Inc.
  • Umecrine Mood AB
  • Umecrine Mood AB
  • Novartis AG
  • GlaxoSmithKline Plc
図表

List of Tables

  • TABLE 1 Global Pre-Menstrual Syndrome Treatment Market By Drugs Type, 2020-2030, USD (Million)
  • TABLE 2 North America Pre-Menstrual Syndrome Treatment Market By Drugs Type, 2020-2030, USD (Million)
  • TABLE 3 U.S. Pre-Menstrual Syndrome Treatment Market By Drugs Type, 2020-2030, USD (Million)
  • TABLE 4 Canada Pre-Menstrual Syndrome Treatment Market By Drugs Type, 2020-2030, USD (Million)
  • TABLE 5 Rest of North America Pre-Menstrual Syndrome Treatment Market By Drugs Type, 2020-2030, USD (Million)
  • TABLE 6 UK and European Union Pre-Menstrual Syndrome Treatment Market By Drugs Type, 2020-2030, USD (Million)
  • TABLE 7 UK Pre-Menstrual Syndrome Treatment Market By Drugs Type, 2020-2030, USD (Million)
  • TABLE 8 Germany Pre-Menstrual Syndrome Treatment Market By Drugs Type, 2020-2030, USD (Million)
  • TABLE 9 Spain Pre-Menstrual Syndrome Treatment Market By Drugs Type, 2020-2030, USD (Million)
  • TABLE 10 Italy Pre-Menstrual Syndrome Treatment Market By Drugs Type, 2020-2030, USD (Million)
  • TABLE 11 France Pre-Menstrual Syndrome Treatment Market By Drugs Type, 2020-2030, USD (Million)
  • TABLE 12 Rest of Europe Pre-Menstrual Syndrome Treatment Market By Drugs Type, 2020-2030, USD (Million)
  • TABLE 13 Asia Pre-Menstrual Syndrome Treatment Market By Drugs Type, 2020-2030, USD (Million)
  • TABLE 14 China Pre-Menstrual Syndrome Treatment Market By Drugs Type, 2020-2030, USD (Million)
  • TABLE 15 Japan Pre-Menstrual Syndrome Treatment Market By Drugs Type, 2020-2030, USD (Million)
  • TABLE 16 India Pre-Menstrual Syndrome Treatment Market By Drugs Type, 2020-2030, USD (Million)
  • TABLE 17 Australia Pre-Menstrual Syndrome Treatment Market By Drugs Type, 2020-2030, USD (Million)
  • TABLE 18 South Korea Pre-Menstrual Syndrome Treatment Market By Drugs Type, 2020-2030, USD (Million)
  • TABLE 19 Latin America Pre-Menstrual Syndrome Treatment Market By Drugs Type, 2020-2030, USD (Million)
  • TABLE 20 Brazil Pre-Menstrual Syndrome Treatment Market By Drugs Type, 2020-2030, USD (Million)
  • TABLE 21 Mexico Pre-Menstrual Syndrome Treatment Market By Drugs Type, 2020-2030, USD (Million)
  • TABLE 22 Rest of Latin America Pre-Menstrual Syndrome Treatment Market By Drugs Type, 2020-2030, USD (Million)
  • TABLE 23 Middle East and Africa Pre-Menstrual Syndrome Treatment Market By Drugs Type, 2020-2030, USD (Million)
  • TABLE 24 GCC Pre-Menstrual Syndrome Treatment Market By Drugs Type, 2020-2030, USD (Million)
  • TABLE 25 Africa Pre-Menstrual Syndrome Treatment Market By Drugs Type, 2020-2030, USD (Million)
  • TABLE 26 Rest of Middle East and Africa Pre-Menstrual Syndrome Treatment Market By Drugs Type, 2020-2030, USD (Million)

List of Figures

  • FIG. 1 Global Pre-Menstrual Syndrome Treatment Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Pre-Menstrual Syndrome Treatment Market: Quality Assurance
  • FIG. 5 Global Pre-Menstrual Syndrome Treatment Market, By Drugs Type, 2021
  • FIG. 6 Global Pre-Menstrual Syndrome Treatment Market, By Geography, 2021
  • FIG. 7 Market Geographical Opportunity Matrix - Global Pre-Menstrual Syndrome Treatment Market, 2021
  • FIG. 8 Market Positioning of Key Pre-Menstrual Syndrome Treatment Market Players, 2021
  • FIG. 9 Global Pre-Menstrual Syndrome Treatment Market - Tier Analysis - Percentage of Revenues by Tier Level, 2021 Versus 2030
  • FIG. 10 Global Pre-Menstrual Syndrome Treatment Market, By Drugs Type, 2021 Vs 2030, %
  • FIG. 11 U.S. Pre-Menstrual Syndrome Treatment Market (US$ Million), 2020 - 2030
  • FIG. 12 Canada Pre-Menstrual Syndrome Treatment Market (US$ Million), 2020 - 2030
  • FIG. 13 Rest of North America Pre-Menstrual Syndrome Treatment Market (US$ Million), 2020 - 2030
  • FIG. 14 UK Pre-Menstrual Syndrome Treatment Market (US$ Million), 2020 - 2030
  • FIG. 15 Germany Pre-Menstrual Syndrome Treatment Market (US$ Million), 2020 - 2030
  • FIG. 16 Spain Pre-Menstrual Syndrome Treatment Market (US$ Million), 2020 - 2030
  • FIG. 17 Italy Pre-Menstrual Syndrome Treatment Market (US$ Million), 2020 - 2030
  • FIG. 18 France Pre-Menstrual Syndrome Treatment Market (US$ Million), 2020 - 2030
  • FIG. 19 Rest of Europe Pre-Menstrual Syndrome Treatment Market (US$ Million), 2020 - 2030
  • FIG. 20 China Pre-Menstrual Syndrome Treatment Market (US$ Million), 2020 - 2030
  • FIG. 21 Japan Pre-Menstrual Syndrome Treatment Market (US$ Million), 2020 - 2030
  • FIG. 22 India Pre-Menstrual Syndrome Treatment Market (US$ Million), 2020 - 2030
  • FIG. 23 Australia Pre-Menstrual Syndrome Treatment Market (US$ Million), 2020 - 2030
  • FIG. 24 South Korea Pre-Menstrual Syndrome Treatment Market (US$ Million), 2020 - 2030
  • FIG. 25 Rest of Asia Pre-Menstrual Syndrome Treatment Market (US$ Million), 2020 - 2030
  • FIG. 26 Brazil Pre-Menstrual Syndrome Treatment Market (US$ Million), 2020 - 2030
  • FIG. 27 Mexico Pre-Menstrual Syndrome Treatment Market (US$ Million), 2020 - 2030
  • FIG. 28 Rest of Latin America Pre-Menstrual Syndrome Treatment Market (US$ Million), 2020 - 2030
  • FIG. 29 GCC Pre-Menstrual Syndrome Treatment Market (US$ Million), 2020 - 2030
  • FIG. 30 Africa Pre-Menstrual Syndrome Treatment Market (US$ Million), 2020 - 2030
  • FIG. 31 Rest of Middle East and Africa Pre-Menstrual Syndrome Treatment Market (US$ Million), 2020 - 2030
目次
Product Code: 137381-08-22

Pre-menstrual syndrome (PMS) is a medical condition in women that occurs during childbearing age. It is estimated that more than one in three women suffer from PMS; and one in every twenty women demonstrate life disturbing symptoms. Pre-menstrual dysphoric disorder (PMDD) is a further severe form of PMS and demonstrates more severe symptoms of PMS, often interfering with social activities, work and emotional balance. PMDD occurs in 3% to 5% of menstruating women. Though the exact cause of PMS is unknown, it is reported that fluctuating levels of hormones (estrogen and progesterone) are related to PMS symptoms. The treatment regimen of PMS is temporary i.e. administered only for symptom management before the onset of menstrual cycle. Education, nutrition, exercise and medication together form the complete layout of PMS treatment module.

The report titled "Pre-menstrual Syndrome Treatment Market - Growth, Future Prospects and Competitive Analysis, 2022-2030" offers strategic insights into the overall pre-menstrual syndrome treatment market along with the market size and estimates for the duration 2020 to 2030. The said research study covers in-depth analysis of multiple market segments based on type of drugs and different geographies. The drug types studied for analyzing the overall global pre-menstrual syndrome treatment market are majorly segmented into analgesics (pain killers), oral contraceptive pills (OCPs), gonadotropin-releasing hormone (GnRH), antidepressants, ovarian suppressors, diuretics and benzodiazepines.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global pre-menstrual syndrome treatment market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global pre-menstrual syndrome treatment market. This report concludes with company profiles section that highlights major information about the key players engaged in global pre-menstrual syndrome treatment market. In-depth competitive environment analysis and historical (2020) market size data are also provided in the report.

Common painkillers available for treating PMS are NSAIDS and paracetamol. This segment is majorly dominated by over-the-counter drugs that are cheap and easily available in the market. For depression and anxiety, particularly in patients with PMDD, drugs such as SSRIs (commonly fluoxetine and sertraline) are commonly prescribed. GnRH i.e. synthetic hormones are prescribed to initiate temporary menopause in patients with severe PMS. It is observed that the demand for hormone-based PMS treatments is on a perpetual rise and will continue through the forecast period.

At present, North America and Europe dominate the premenstrual syndrome treatment market due to increase in prevalence of premenstrual syndrome and higher awareness about syndrome and prevailing treatment options. Asia Pacific and Middle East and Africa together present lucrative opportunities to manufacturers offering PMS treatment drugs. Large pool of females in childbearing age, growing literacy rate and working population significantly contribute to growing opportunities in the region. Growing number of government initiatives and campaigns focusing on women and maternity health are further driving the market growth.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Pre-Menstrual Syndrome Treatment market are as follows:

  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Pre-Menstrual Syndrome Treatment market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Drugs Type

  • Analgesics (pain killers)
  • Oral Contraceptive Pills (OCPs)
  • Gonadotropin-releasing Hormone (GnRH)
  • Antidepressants
  • Ovarian Suppressors
  • Diuretics
  • Benzodiazepines

Region Segment (2020-2030; US$ Million)

  • North America
    • U.S.
    • Canada
    • Rest of North America
  • UK and European Union
    • UK
    • Germany
    • Spain
    • Italy
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Africa
    • Rest of Middle East and Africa

Global Impact of COVID-19 Segment (2020-2021; US$ Million )

  • Pre COVID-19 situation
  • Post COVID-19 situation

Key questions answered in this report:

  • What are the key micro and macro environmental factors that are impacting the growth of Pre-Menstrual Syndrome Treatment market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2030.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Pre-Menstrual Syndrome Treatment market?
  • Which is the largest regional market for Pre-Menstrual Syndrome Treatment market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Pre-Menstrual Syndrome Treatment market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Pre-Menstrual Syndrome Treatment market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Pre-Menstrual Syndrome Treatment Market
  • 2.2. Global Pre-Menstrual Syndrome Treatment Market, By Drugs Type, 2021 (US$ Million)
  • 2.3. Global Pre-Menstrual Syndrome Treatment Market, By Geography, 2021 (US$ Million)
  • 2.4. Attractive Investment Proposition by Geography, 2021

3. Pre-Menstrual Syndrome Treatment Market: Competitive Analysis

  • 3.1. Market Positioning of Key Pre-Menstrual Syndrome Treatment Market Vendors
  • 3.2. Strategies Adopted by Pre-Menstrual Syndrome Treatment Market Vendors
  • 3.3. Key Industry Strategies
  • 3.4. Tier Analysis 2021 Versus 2030

4. Pre-Menstrual Syndrome Treatment Market: Macro Analysis & Market Dynamics

  • 4.1. Introduction
  • 4.2. Global Pre-Menstrual Syndrome Treatment Market Value, 2020 - 2030, (US$ Million)
  • 4.3. Market Dynamics
    • 4.3.1. Market Drivers
    • 4.3.2. Market Restraints
    • 4.3.3. Key Challenges
    • 4.3.4. Key Opportunities
  • 4.4. Impact Analysis of Drivers and Restraints
  • 4.5. See-Saw Analysis

5. Pre-Menstrual Syndrome Treatment Market: By Drugs Type, 2020-2030, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2021 Versus 2030
  • 5.3. Market Segmentation
    • 5.3.1. Analgesics (pain killers)
    • 5.3.2. Oral Contraceptive Pills (OCPs)
    • 5.3.3. Gonadotropin-releasing Hormone (GnRH)
    • 5.3.4. Antidepressants
    • 5.3.5. Ovarian Suppressors
    • 5.3.6. Diuretics
    • 5.3.7. Benzodiazepines

6. North America Pre-Menstrual Syndrome Treatment Market, 2020-2030, USD (Million)

  • 6.1. Market Overview
  • 6.2. Pre-Menstrual Syndrome Treatment Market: By Drugs Type, 2020-2030, USD (Million)
  • 6.3.Pre-Menstrual Syndrome Treatment Market: By Region, 2020-2030, USD (Million)
    • 6.3.1.North America
      • 6.3.1.1. U.S.
        • 6.3.1.1.1. Pre-Menstrual Syndrome Treatment Market: By Drugs Type, 2020-2030, USD (Million)
      • 6.3.1.2. Canada
        • 6.3.1.2.1. Pre-Menstrual Syndrome Treatment Market: By Drugs Type, 2020-2030, USD (Million)
      • 6.3.1.3. Rest of North America
        • 6.3.1.3.1. Pre-Menstrual Syndrome Treatment Market: By Drugs Type, 2020-2030, USD (Million)

7. UK and European Union Pre-Menstrual Syndrome Treatment Market, 2020-2030, USD (Million)

  • 7.1. Market Overview
  • 7.2. Pre-Menstrual Syndrome Treatment Market: By Drugs Type, 2020-2030, USD (Million)
  • 7.3.Pre-Menstrual Syndrome Treatment Market: By Region, 2020-2030, USD (Million)
    • 7.3.1.UK and European Union
      • 7.3.1.1. UK
        • 7.3.1.1.1. Pre-Menstrual Syndrome Treatment Market: By Drugs Type, 2020-2030, USD (Million)
      • 7.3.1.2. Germany
        • 7.3.1.2.1. Pre-Menstrual Syndrome Treatment Market: By Drugs Type, 2020-2030, USD (Million)
      • 7.3.1.3. Spain
        • 7.3.1.3.1. Pre-Menstrual Syndrome Treatment Market: By Drugs Type, 2020-2030, USD (Million)
      • 7.3.1.4. Italy
        • 7.3.1.4.1. Pre-Menstrual Syndrome Treatment Market: By Drugs Type, 2020-2030, USD (Million)
      • 7.3.1.5. France
        • 7.3.1.5.1. Pre-Menstrual Syndrome Treatment Market: By Drugs Type, 2020-2030, USD (Million)
      • 7.3.1.6. Rest of Europe
        • 7.3.1.6.1. Pre-Menstrual Syndrome Treatment Market: By Drugs Type, 2020-2030, USD (Million)

8. Asia Pacific Pre-Menstrual Syndrome Treatment Market, 2020-2030, USD (Million)

  • 8.1. Market Overview
  • 8.2. Pre-Menstrual Syndrome Treatment Market: By Drugs Type, 2020-2030, USD (Million)
  • 8.3.Pre-Menstrual Syndrome Treatment Market: By Region, 2020-2030, USD (Million)
    • 8.3.1.Asia Pacific
      • 8.3.1.1. China
        • 8.3.1.1.1. Pre-Menstrual Syndrome Treatment Market: By Drugs Type, 2020-2030, USD (Million)
      • 8.3.1.2. Japan
        • 8.3.1.2.1. Pre-Menstrual Syndrome Treatment Market: By Drugs Type, 2020-2030, USD (Million)
      • 8.3.1.3. India
        • 8.3.1.3.1. Pre-Menstrual Syndrome Treatment Market: By Drugs Type, 2020-2030, USD (Million)
      • 8.3.1.4. Australia
        • 8.3.1.4.1. Pre-Menstrual Syndrome Treatment Market: By Drugs Type, 2020-2030, USD (Million)
      • 8.3.1.5. South Korea
        • 8.3.1.5.1. Pre-Menstrual Syndrome Treatment Market: By Drugs Type, 2020-2030, USD (Million)
      • 8.3.1.6. Rest of Asia Pacific
        • 8.3.1.6.1. Pre-Menstrual Syndrome Treatment Market: By Drugs Type, 2020-2030, USD (Million)

9. Latin America Pre-Menstrual Syndrome Treatment Market, 2020-2030, USD (Million)

  • 9.1. Market Overview
  • 9.2. Pre-Menstrual Syndrome Treatment Market: By Drugs Type, 2020-2030, USD (Million)
  • 9.3.Pre-Menstrual Syndrome Treatment Market: By Region, 2020-2030, USD (Million)
    • 9.3.1.Latin America
      • 9.3.1.1. Brazil
        • 9.3.1.1.1. Pre-Menstrual Syndrome Treatment Market: By Drugs Type, 2020-2030, USD (Million)
      • 9.3.1.2. Mexico
        • 9.3.1.2.1. Pre-Menstrual Syndrome Treatment Market: By Drugs Type, 2020-2030, USD (Million)
      • 9.3.1.3. Rest of Latin America
        • 9.3.1.3.1. Pre-Menstrual Syndrome Treatment Market: By Drugs Type, 2020-2030, USD (Million)

10. Middle East and Africa Pre-Menstrual Syndrome Treatment Market, 2020-2030, USD (Million)

  • 10.1. Market Overview
  • 10.2. Pre-Menstrual Syndrome Treatment Market: By Drugs Type, 2020-2030, USD (Million)
  • 10.3.Pre-Menstrual Syndrome Treatment Market: By Region, 2020-2030, USD (Million)
    • 10.3.1.Middle East and Africa
      • 10.3.1.1. GCC
        • 10.3.1.1.1. Pre-Menstrual Syndrome Treatment Market: By Drugs Type, 2020-2030, USD (Million)
      • 10.3.1.2. Africa
        • 10.3.1.2.1. Pre-Menstrual Syndrome Treatment Market: By Drugs Type, 2020-2030, USD (Million)
      • 10.3.1.3. Rest of Middle East and Africa
        • 10.3.1.3.1. Pre-Menstrual Syndrome Treatment Market: By Drugs Type, 2020-2030, USD (Million)

11. Company Profile

  • 11.1. Alva-Amco Pharmacal Cos., Inc.
    • 11.1.1. Company Overview
    • 11.1.2. Financial Performance
    • 11.1.3. Product Portfolio
    • 11.1.4. Strategic Initiatives
  • 11.2. Bayer, Inc.
    • 11.2.1. Company Overview
    • 11.2.2. Financial Performance
    • 11.2.3. Product Portfolio
    • 11.2.4. Strategic Initiatives
  • 11.3. Chattem, Inc. (Sanofi)
    • 11.3.1. Company Overview
    • 11.3.2. Financial Performance
    • 11.3.3. Product Portfolio
    • 11.3.4. Strategic Initiatives
  • 11.4. DEKK-TEC, Inc.
    • 11.4.1. Company Overview
    • 11.4.2. Financial Performance
    • 11.4.3. Product Portfolio
    • 11.4.4. Strategic Initiatives
  • 11.5. G. R. Lane Health Products Ltd
    • 11.5.1. Company Overview
    • 11.5.2. Financial Performance
    • 11.5.3. Product Portfolio
    • 11.5.4. Strategic Initiatives
  • 11.6. McNeil Consumer Healthcare
    • 11.6.1. Company Overview
    • 11.6.2. Financial Performance
    • 11.6.3. Product Portfolio
    • 11.6.4. Strategic Initiatives
  • 11.7. MetP Pharma AG
    • 11.7.1. Company Overview
    • 11.7.2. Financial Performance
    • 11.7.3. Product Portfolio
    • 11.7.4. Strategic Initiatives
  • 11.8. Pherin Pharmaceuticals, Inc.
    • 11.8.1. Company Overview
    • 11.8.2. Financial Performance
    • 11.8.3. Product Portfolio
    • 11.8.4. Strategic Initiatives
  • 11.9. Umecrine Mood AB
    • 11.9.1. Company Overview
    • 11.9.2. Financial Performance
    • 11.9.3. Product Portfolio
    • 11.9.4. Strategic Initiatives
  • 11.10. Umecrine Mood AB
    • 11.10.1. Company Overview
    • 11.10.2. Financial Performance
    • 11.10.3. Product Portfolio
    • 11.10.4. Strategic Initiatives
  • 11.11. Novartis AG
    • 11.11.1. Company Overview
    • 11.11.2. Financial Performance
    • 11.11.3. Product Portfolio
    • 11.11.4. Strategic Initiatives
  • 11.12. GlaxoSmithKline Plc
    • 11.12.1. Company Overview
    • 11.12.2. Financial Performance
    • 11.12.3. Product Portfolio
    • 11.12.4. Strategic Initiatives